Effects of buprenorphine, methadone, and cariprazine on economic choice between remifentanil and food in squirrel monkeys

Amirali, Alishan S.; Hecker, Jacquelin C.; Figueroa, Hector M.; Effinger, Devin P.; Montoro, Rodrigo A.; Jedema, Hank P.; Vogt, Caleb D.; Newman, Amy Hauck; Schindler, Charles W.; Bradberry, Charles W.

doi:10.1016/j.addicn.2023.100065

Cited by 1 publication

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, acute pretreatment with the D3R partial agonist/antagonist (±)VK4‐40 decreased oxycodone self‐administration and oxycodone‐induced reinstatement in both rats and monkeys 12,13 . However, chronic pharmacological treatment to model current clinical OUD medication dosing regimens with the D3R partial agonist cariprazine failed to decrease remifentanil self‐administration in monkeys 14 . Potential reasons for the differential results between cariprazine and the VK4‐40 D3R partial agonist studies could be related to either experimental design considerations such as acute vs. repeated dosing of the D3R partial agonist or differences in test compound pharmacological selectivity for the D3R versus D2R.…”

Section: Introductionmentioning

confidence: 99%

“…12,13 However, chronic pharmacological treatment to model current clinical OUD medication dosing regimens with the D3R partial agonist cariprazine failed to decrease remifentanil self-administration in monkeys. 14 Potential reasons for the differential results between cariprazine and the VK4-40 D3R partial agonist studies could be related to either experimental design considerations such as acute vs. repeated dosing of the D3R partial agonist or differences in test compound pharmacological selectivity for the D3R versus D2R. Additionally, the R-enantiomer of VK4-40 has been determined to be an antagonist and the S-enantiomer a partial agonist of the D3R.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder

Banks,

Sprague

2024

Addiction Biology

View full text Add to dashboard Cite

Here, we present recent studies suggesting that specific DRD3 single nucleotide polymorphisms (SNPs, e.g. rs324029 and rs2654754) might serve as prognostic biomarkers for opioid use disorder (OUD). Additionally, preclinical studies with novel dopamine 3 receptor (D3R) partial agonists and antagonists have been evaluated as candidate OUD therapeutics and have shown a reduced risk of cardiovascular toxicity compared with the original D3R antagonist. From these findings, we argue that DRD3 SNPs could serve as a diagnostic tool for assessing OUD risk and that more research is warranted examining the D3R as a safe and effective therapeutic target for treating OUD.

show abstract

Section: Introductionmentioning

confidence: 99%